EP0334530A1
Expired / Lapsed
EP
⏱️ 0.0 years remaining
A recombinant marek's disease virus and a vaccine
Assignee: Research Foundation for Microbial Diseases of Osaka University
•
Filing: 1989-03-14
•
Granted: —
•
Expires: 2009-03-14
Abstract
Abstract There is provided a recombinant Marek's disease virus comprising the genomic DNA of an attenuated Marek's disease virus and a foreign gene from another source. The present recombinant virus can advantageously be used as an active ingredient for a multifunctional live vaccine, exhibiting not only the antigenicity and immunogenicity of the Marek's disease virus but also the properties ascribed to the foreign gene. Since the suitable host cell for the recombinant virus of the present invention is an avian cell which is available in a large quantity and not expensive, the recombinant virus of the present invention can be produced efficiently at low cost on a commercial scale.
Inventors
- 👤 Toyokazu Ishikawa
- 👤 Sadao Manabe
- 👤 Chisato Mori
- 👤 Akihisa Takamizawa
- 👤 Iwao Yoshida
- 👤 Juichiro Osame
- 👤 Keisuke Takaku
- 👤 Konosuke Fukai
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-08 23:46
CPC Classifications
C; C12; C12N; C12N15/00; C12N15/09; C12N15/63; C12N15/79; C12N15/85; C12N15/86; C07; C07K; C07K14/00; C07K14/005; C12N7/00; A; A61; A61K; A61K39/00; C12N2710/00; C12N2710/00011; C12N2710/16011; C12N2710/16311; C12N2710/16322; C12N2710/16341; C12N2710/16343; C12N2760/00; C12N2760/00011; C12N2760/18011; C12N2760/18111; C12N2760/18122; C12N2770/00; C12N2770/00011; C12N2770/20011; C12N2770/20022; Y; Y02; Y02A; Y02A50/00; Y02A50/30
Claims Analysis
Total Claims: 14
Claim 1
Independent Claim
87 words
A recombinant Marek's disease virus comprising the genomic DNA of an attenuated Marek's disease virus and at least one foreign gene derived from another source, wherein said foreign gene is inserted in said genomic DNA in a correct reading frame downstream of at least one promoter of said genomic DNA, which promoter is functional in a host cell for expressing said foreign gene, said recombinant Marek's disease virus having an antigenicity and immunogenicity of a Marek's disease virus and containing a polypeptide encoded by said foreign gene.
Claim 2
Dependent Claim
87 words
A recombinant Marek's disease virus comprising the genomic DNA of an attenuated Marek's disease virus and at least one foreign gene derived from another source, wherein said foreign gene is inserted in said genomic DNA in a correct reading frame downstream of at least one promoter of said genomic DNA, which promoter is functional in a host cell for expressing said foreign gene, said recombinant Marek's disease virus having an antigenicity and immunogenicity of a Marek's disease virus and containing a polypeptide encoded by said foreign gene.
Claim 3
Dependent Claim
50 words
A recombinant Marek's disease virus according to claim 1, wherein said foreign gene codes for a polypeptide selected from the group consisting of antigens, enzymes, peptide hormones, and structural proteins derived from viruses other than Marek's disease virus and from chlamydia, rickettsia, mycoplasmas, bacteria, protozoa, animal cells and plant cells.
Claim 4
Dependent Claim
37 words
A recombinant Marek's disease virus according to claim 1, wherein said attenuated Marek's disease virus is selected from the group consisting of a Marek's disease virus BIKEN "C2" strain and a herpesvirus of turkeys BIKEN "O1" strain.
Claim 5
Dependent Claim
85 words
A recombinant Marek's disease virus according to claim 1, wherein said promoter is derived from a gene selected from the group consisting of a glycoprotein A antigen gene, a glycoprotein B antigen gene, an antigen C gene, a gene coding for a DNA-binding protein having a molecular weight of about 135,000, genes coding for major virus-specific proteins respectively having molecular weights of about 86,000 and about 92,000, and genes coding for phosphorylated proteins respectively having molecular weights of about 36,000, about 39,000 and about 44,000.
Claim 6
Dependent Claim
108 words
A multifunctional Marek's disease live vaccine comprising: an immunogenic amount of a recombinant Marek's disease virus comprising the genomic DNA of an attenuated Marek's disease virus and at least one foreign gene derived from another source, wherein said foreign gene is inserted in said genomic DNA in a correct reading frame downstream of at least one promoter of said genomic DNA, which promoter is functional in a host cell for expressing said foreign gene, said recombinant Marek's disease virus having an antigenicity and immunogenicity of a Marek's disease virus and containing a polypeptide encoded by said foreign gene; and at least one pharmaceutical acceptable carrier, diluent or excipient.
Claim 7
Dependent Claim
108 words
A multifunctional Marek's disease live vaccine comprising: an immunogenic amount of a recombinant Marek's disease virus comprising the genomic DNA of an attenuated Marek's disease virus and at least one foreign gene derived from another source, wherein said foreign gene is inserted in said genomic DNA in a correct reading frame downstream of at least one promoter of said genomic DNA, which promoter is functional in a host cell for expressing said foreign gene, said recombinant Marek's disease virus having an antigenicity and immunogenicity of a Marek's disease virus and containing a polypeptide encoded by said foreign gene; and at least one pharmaceutical acceptable carrier, diluent or excipient.
Claim 8
Dependent Claim
51 words
A multifunctional Marek's disease live vaccine according to claim 5, wherein said foreign gene codes for a polypeptide selected from the group consisting of antigens, enzymes, peptide hormones, and structural proteins derived from viruses other than Marek's disease virus and from chlamydia, rickettsia, mycoplasmas, bacteria, protozoa, animal cells and plant cells.
Claim 9
Dependent Claim
86 words
A multifunctional Marek's disease live vaccine according to claim 5, wherein said promoter is derived from a gene selected from the group consisting of a glycoprotein A antigen gene, a glycoprotein B antigen gene, an antigen C gene, a gene coding for a DNA-binding protein having a molecular weight of about 135,000, genes coding for major virus-specific proteins respectively having molecular weights of about 86,000 and about 92,000, and genes coding for phosphorylated proteins respectively having molecular weights of about 36,000, about 39,000 and about 44,000.
Claim 10
Independent Claim
143 words
A method for producing a multifunctional Marek's disease live vaccine which comprises: (1) culturing a recombinant Marek's disease virus in an avian cell culture, said recombinant Marek's disease virus comprising the genomic DNA of an attenuated Marek's disease virus and at least one foreign gene derived from another source, wherein said foreign gene is inserted in said genomic DNA in a correct reading frame downstream of at least one promoter of said genomic DNA, which promoter is functional in a host cell for expressing said foreign gene, said recombinant Marek's disease virus having an antigenicity and immunogenicity of a Marek's disease virus and containing a polypeptide encoded by said foreign gene; (2) isolating the multiplied recombinant Marek's disease virus from said avian cell culture; and (3) adding to the resultant recombinant Marek's disease virus at least one pharmaceutically acceptable carrier, diluent or excipient.
Claim 11
Independent Claim
143 words
A method for producing a multifunctional Marek's disease live vaccine which comprises: (1) culturing a recombinant Marek's disease virus in an avian cell culture, said recombinant Marek's disease virus comprising the genomic DNA of an attenuated Marek's disease virus and at least one foreign gene derived from another source, wherein said foreign gene is inserted in said genomic DNA in a correct reading frame downstream of at least one promoter of said genomic DNA, which promoter is functional in a host cell for expressing said foreign gene, said recombinant Marek's disease virus having an antigenicity and immunogenicity of a Marek's disease virus and containing a polypeptide encoded by said foreign gene; (2) isolating the multiplied recombinant Marek's disease virus from said avian cell culture; and (3) adding to the resultant recombinant Marek's disease virus at least one pharmaceutically acceptable carrier, diluent or excipient.
Claim 12
Dependent Claim
47 words
A method according to claim 8, wherein said foreign gene codes for a polypeptide selected from the group consisting of antigens, enzymes, peptide hormones, and structural proteins derived from viruses other than Marek's disease virus and from chlamydia, rickettsia, mycoplasmas, bacteria, protozoa, animal cells and plant cells.
Claim 13
Dependent Claim
82 words
A method according to claim 8, wherein said promoter is derived from a gene selected from the group consisting of a glycoprotein A antigen gene, a glycoprotein B antigen gene, an antigen C gene, a gene coding for a DNA-binding protein having a molecular weight of about 135,000, genes coding for major virus-specific proteins respectively having molecular weights of about 86,000 and about 92,000, and genes coding for phosphorylated proteins respectively having molecular weights of about 36,000, about 39,000 and about 44,000.
Claim 14
Dependent Claim
16 words
A method according to claim 8, comprising, after step (3), subjecting the resultant mixture to lyophilization.
References Cited (Backward Citations)
WO1987000862A1
Cited
WO1988007088A1
Cited
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.